NEW YORK — OpGen said in a filing with the US Securities and Exchange Commission today that it intends to undertake a 20-for-1 reverse stock split.
The disclosure comes less than a week after the Gaithersburg, Maryland-based developer of antibiotic-resistance testing technology said that it had been notified by the Nasdaq that it was out of compliance with the exchange's $2.5 million minimum shareholder equity requirement and faced delisting.
In the SEC filing, OpGen said that the reverse stock split will become effective on Thursday.
During early afternoon trading Wednesday, shares of OpGen were up nearly 12.5 percent at $.28.